v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Reconciles Segment Direct Profit or Loss

The following table reconciles segment direct profit or loss to the Company’s consolidated results:

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

(in thousands)

2025

 

 

2024

 

 

2025

 

 

2024

 

Research and development:

 

 

 

 

 

 

 

 

 

 

 

QTORIN rapamycin for microcystic LM

$

1,235

 

 

$

422

 

 

$

2,389

 

 

$

425

 

QTORIN rapamycin for microcystic LM - Government grant income

 

(212

)

 

 

 

 

 

(339

)

 

 

 

QTORIN rapamycin for cutaneous VM

 

354

 

 

 

 

 

 

700

 

 

 

 

QTORIN rapamycin CMC

 

1,517

 

 

 

40

 

 

 

2,289

 

 

 

153

 

Non-program specific and unallocated research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

Salaries and stock-based compensation

 

1,501

 

 

 

704

 

 

 

2,823

 

 

 

1,351

 

Consultants

 

385

 

 

 

183

 

 

 

632

 

 

 

351

 

Other

 

338

 

 

 

93

 

 

 

698

 

 

 

146

 

Total research and development

$

5,118

 

 

$

1,442

 

 

$

9,192

 

 

$

2,426

 

General and administrative:

 

 

 

 

 

 

 

 

 

 

 

Salaries and stock-based compensation

$

1,744

 

 

$

411

 

 

$

3,197

 

 

$

757

 

Consultants

 

914

 

 

 

786

 

 

 

1,910

 

 

 

946

 

Other

 

1,474

 

 

 

269

 

 

 

2,822

 

 

 

538

 

Total general and administrative

$

4,132

 

 

$

1,466

 

 

$

7,929

 

 

$

2,241

 

Loss from operations

$

(9,250

)

 

$

(2,908

)

 

$

(17,121

)

 

$

(4,667

)